Products for Research Use Only
RegisterLogin

Icariside I

CAT: 0804-HY-N1939-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N1939-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Icariside I (GH01) is an orally active metabolite of icalin. Icariside I improves estrogen deficiency-induced osteoporosis by simultaneously regulating osteoblast and osteoclast differentiation. Icariside I promotes ATP or Nigericin (HY-127019) -induced mtROS production and NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Icariside I does not alter the activation of NLRC4 and AIM2 inflammasomes. Icariside I inhibits breast cancer proliferation, apoptosis, invasion, and metastasis by targeting the IL-6/STAT3 pathway. Icariside I is a kynurenine-AhR pathway inhibitor that alleviates cancer by blocking tumor immune escape[1][2][3][4].
CAS Number
56725-99-6
Product Name Alternative
Icarisid I
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Aryl Hydrocarbon Receptor; Bcl-2 Family; Caspase; CDK; IFNAR; JAK; NOD-like Receptor (NLR) ; PD-1/PD-L1; Reactive Oxygen Species (ROS) ; STAT
Type
Natural Products
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer; Endocrinology; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Icariside_I.html
Purity
99.30
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(C/C=C(C)\C)C(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)=CC(O)=C13
Molecular Formula
C27H30O11
Molecular Weight
530.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Gao Y, et al. Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Cell Commun Signal. 2021 Feb 11;19 (1) :13.|[2]Hou M, et al. Icariside I reduces breast cancer proliferation, apoptosis, invasion, and metastasis probably through inhibiting IL-6/STAT3 signaling pathway. J Pharm Pharmacol. 2024 May 3;76 (5) :499-513.|[3]Chen G, et al. Icariside I - A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape. Biomed Pharmacother. 2022 Sep;153:113387.|[4]Chen C, et al. A Novel Prenylflavonoid Icariside I Ameliorates Estrogen Deficiency-Induced Osteoporosis via Simultaneous Regulation of Osteoblast and Osteoclast Differentiation. ACS Pharmacol Transl Sci. 2023 Jan 13;6 (2) :270-280.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Isoform
NLRP3

Related Products

CatalogName
HY-N7450Icariside D2
HY-N15531Icariside D1
HY-N4020Icariside E5
HY-N8083-01Icariside B1
HY-N13660-01Icariside B5
HY-N9854-01Icariside E4
HY-N8085-01Icariside F2
HY-E70040Endoglycoceramidase I (EGCase I)
HY-KE7028Not I
HY-KE8010Exonuclease I

Alternative Products

CatalogName
BFA25342-01Icariside E4
MBS579784Icariside I
GTR19183739-01Icariside F2
GTR19256468-01Icariside D1
BFA17679-01Icariside E5
TN4244Icariside B1
GTR19181351Icariside D2

Popular Products